Protecting Patient Access to Cancer and Complex Therapies Act
The source supplies the latest action, but no lifecycle stage.
Latest action (7 Jul 2025): Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
What this bill does
H.R. 4299, the Protecting Patient Access to Cancer and Complex Therapies Act, would amend Medicare Part B to require manufacturers of certain drugs and biological products to provide rebates. These "selected drugs" are those subject to a maximum fair price negotiation. The bill outlines a process where the Secretary of Health and Human Services would provide manufacturers with data on the number of units of these drugs dispensed and calculate a potential rebate amount. Manufacturers would then be required to pay a rebate based on this calculation.
This legislation primarily affects Medicare beneficiaries receiving these selected drugs and the manufacturers of those drugs. For beneficiaries, the bill aims to adjust coinsurance amounts based on a "maximum fair price plus 6 percent" calculation. For manufacturers, it introduces a new rebate requirement that is in addition to any other existing rebates. The bill specifies that these rebate amounts would be deposited into the Federal Supplementary Medical Insurance Trust Fund.
The bill was introduced in the House of Representatives on July 7, 2025, and has been referred to the Committees on Energy and Commerce and Ways and Means. No further action has been taken since its introduction. If the bill were to advance, it would need to pass through these committees and then be voted on by the full House, followed by a similar process in the Senate before it could be sent to the President.
Plain-English summary generated by Bill100 AI from the official record. Always verify against the source below.
Timeline
7 Jul 2025
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Common questions
- What does H.R. 4299 do?
- H.R. 4299, the Protecting Patient Access to Cancer and Complex Therapies Act, would amend Medicare Part B to require manufacturers of certain drugs and biological products to provide rebates. These "selected drugs" are those subject to a maximum fair price negotiation. The bill outlines a process where the Secretary of Health and Human Services would provide manufacturers with data on the number of units of these drugs dispensed and calculate a potential rebate amount. Manufacturers would then be required to pay a rebate based on this calculation. This legislation primarily affects Medicare beneficiaries receiving these selected drugs and the manufacturers of those drugs. For beneficiaries, the bill aims to adjust coinsurance amounts based on a "maximum fair price plus 6 percent" calculation. For manufacturers, it introduces a new rebate requirement that is in addition to any other existing rebates. The bill specifies that these rebate amounts would be deposited into the Federal Supplementary Medical Insurance Trust Fund. The bill was introduced in the House of Representatives on July 7, 2025, and has been referred to the Committees on Energy and Commerce and Ways and Means. No further action has been taken since its introduction. If the bill were to advance, it would need to pass through these committees and then be voted on by the full House, followed by a similar process in the Senate before it could be sent to the President.
- Has H.R. 4299 become law?
- The source does not supply a confirmed lifecycle stage for H.R. 4299. Check the latest action and official source below.
- Who sponsored H.R. 4299?
- H.R. 4299 was sponsored by Rep. Murphy, Gregory F. [R-NC-3] (R-NC), with 57 cosponsors.
- What's the latest action on H.R. 4299?
- Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. (7 Jul 2025).
Related bills in Health
Choices for Increased Mobility Act of 2026
Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
Access to Medical Supplies Act
Lower Premiums, Faster Payments Act
More bills from Rep. Murphy, Gregory F. [R-NC-3]
Access to Medical Supplies Act
Responsible Artificial Intelligence for Veterans Act of 2026
MAP for Care Act
VA Research Reform Act of 2025
Bill100 mirrors the public U.S. legislative record from Congress.gov and GovTrack and adds plain-English AI summaries. It is an information tool, not legal, compliance or lobbying advice, and it is not affiliated with the U.S. Congress or any government agency. AI summaries can simplify or omit detail — every bill links to the official source; verify there before you rely on it.